Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Otlertuzumab||TRU-016|TRU016|TRU 016||CD37 Antibody 6||Otlertuzumab (TRU-016) is a anti-CD37 therapeutic protein, which may result in increased antibody-dependent cellular cytotoxicity and decreased tumor cell growth (PMID: 24381226, PMID: 25146490, PMID: 27977057).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||non-Hodgkin lymphoma||not applicable||Otlertuzumab||Phase I||Actionable||In a Phase I trial, Otlertuzumab (TRU-016) was well-tolerated and demonstrated some preliminary efficacy in non-Hodgkin lymphoma patients (PMID: 25146490).||25146490|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|